Pfizer’s treatment for ulcerative colitis approved in Europe

European Commission has approved Pfizer’s Xeljanz (tofacitinib citrate) for ulcerative colitis (UC), meaning it is the first oral therapy and Janus kinase inhibitor to be approved for this patient population. The drug is now approved for three indications in the EU, which also includes rheumatoid arthritis and psoriatic arthritis. “Until now, people living with moderately

Continue Reading

NICE Issue Draft Guidance for Pfizer’s Lung Cancer Drug but Removes Janssen and Novartis Drugs from Funding.

NICE have issued new draft guidance in the UK meaning some patients with lung cancer will be eligible for treatment with Pfizer’s Xalkori, reversing an earlier rejection. NICE recommended ALK inhibitor Xalkori for NHS use after Pfizer agreed to markdown the drug’s price for the second time. An earlier reduction from its £51,000-a-year UK list

Continue Reading

Merck and Pfizer receive FDA Breakthrough Therapy designation for Avelumab

Merck and Pfizer today announced that the FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with metastatic Merkel cell carcinoma (MCC) that have progressed after at least one previous chemotherapy regimen. Breakthrough Therapy designation is designed to accelerate the development and review of

Continue Reading